Take a Label Claim, and Pay Me in the Morning: A Challenge to FDA's Argument that its Final Rule (Jan. 2000) on Structure/Function Claims for Dietary Supplements Does Not Constitute a Compensable Regulatory Taking Under the Fifth Amendment

Take a Label Claim, and Pay Me in the Morning: A Challenge to FDA's Argument that its Final Rule (Jan. 2000) on Structure/Function Claims for Dietary Supplements Does Not Constitute a Compensable Regulatory Taking Under the Fifth Amendment

DSpace/Manakin Repository

Take a Label Claim, and Pay Me in the Morning: A Challenge to FDA's Argument that its Final Rule (Jan. 2000) on Structure/Function Claims for Dietary Supplements Does Not Constitute a Compensable Regulatory Taking Under the Fifth Amendment

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	McCants, William D.	en_US
dc.date.accessioned	2012-07-06T21:38:31Z
dc.date.issued	2000	en_US
dc.identifier.citation	Take a Label Claim, and Pay Me in the Morning: A Challenge to FDA's Argument that its Final Rule (Jan. 2000) on Structure/Function Claims for Dietary Supplements Does Not Constitute a Compensable Regulatory Taking Under the Fifth Amendment (2000 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965592
dc.description.abstract	On January 6, 2000, the Food and Drug Administration ("FDA") published its final rule prescribing the kinds of statements which can be made about the effect of a dietary supplement on the structure or function of the body ("structure/function" claims), in accordance with the Dietary Supplement Health and Education Act of 1994 ("DSHEA"). Under DSHEA, dietary supplements can bear structure/function claims without prior FDA review. But they cannot, without such prior review, bear a claim that they can prevent, treat, cure, mitigate or diagnose disease ("disease claim"). One of the most controversial aspects of the final rule, and the subject of this paper, is FDA's regulation of what the agency chooses to call "implied disease claims": The final rule precludes express disease claims ("prevent[s] osteoporosis") and implied disease claims ("prevents bone fragility in post-menopausal women") without prior FDA review. The final rule clarifies that such express and implied disease claims can be made through the name of a product ("Carpaltum," "CircuCure"), through a statement about the formulation of a product (contains aspirin), or through the use of pictures, vignettes, or symbols (electrocardiogram tracings). The rule permits claims that do not relate to disease. These include health maintenance claims ("maintains a healthy circulatory system"), other non-disease claims ("for muscle enhancement," "helps you relax,"), and claims for common, minor symptoms associated with life stages ("for common symptoms of PMS," "for hot flashes").	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	FDA	en
dc.subject	DSHEA	en
dc.subject	disease	en
dc.subject	claims	en
dc.subject	drugs	en
dc.subject	Fifth Amendment	en
dc.subject	Final Rule	en
dc.title	Take a Label Claim, and Pay Me in the Morning: A Challenge to FDA's Argument that its Final Rule (Jan. 2000) on Structure/Function Claims for Dietary Supplements Does Not Constitute a Compensable Regulatory Taking Under the Fifth Amendment	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T21:38:31Z